Page 409 - شرور شركات الأدوية

‫ﻣﻼﺣﻈﺎت‬

(85) This is a vast story, told well elsewhere. Start with Curfman GD,
Morrissey S, Drazen JM. Expression of concern reaffirmed. N. Engl. J. Med.
2006 Mar 16;354(11):1193.

(86) Opinion: Misleading Drug Trials. The Scientist [Internet]. [cited
2012 May 15]. Available from: http://the-scientist.com/2012/05/14/
opinion-misleading-drug-trials/.

(87) The Yale Open Data Archive project, or YODA, is one good exam-
ple of how this might look in the future.

(88) Clarke M, Clarke L, Clarke T. Yes Sir, no Sir, not much difference
Sir. JRSM. 2007 Dec 1;100(12):571-572.

(89) Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ. Impact of
covert duplicate publication on meta-analysis: a case study. BMJ. 1997 Sep
13;315(7109):635–40.

‫ ﻣﻦ أﻳﻦ ﺗﺄﺗﻲ اﻟﻌﻘﺎﻗير اﻟﺠﺪﻳﺪة؟‬:‫اﻟﻔﺼﻞ اﻟﺜﺎﻧﻲ‬

(1) I recommend the classic medical student textbook ‘Rang and Dale’:
Rang & Dale’s Pharmacology. 6th ed. Churchill Livingstone; 2007. But also
this, on the regulatory process around early drug development: Friedhoff
LT. New Drugs: An Insider’s Guide to the FDA’s New Drug Approval Process
for Scientists, Investors and Patients. 1st ed. PSPG Publishing, 2009.

(2) Elliott C, Abadie R. Exploiting a research underclass in phase 1
clinical trials. New England Journal of Medicine. 2008;358(22):2316.

(3) Cohen LP. To screen new drugs for safety, Lilly pays homeless al-
coholics: it’s ‘quick cash’ to habitues of Indianapolis shelters; it vanishes
quickly, too. Wall St J (East Ed). 1996 Nov 14;A1, A10.

(4) Abadie R. The Professional Guinea Pig: Big Pharma and the Risky
World of Human Subjects. 1st ed. Duke University Press, 2010.

(5) Helms R, editor. Guinea Pig Zero: An Anthology of the Journal for
Human Research Subjects. 1st ed. Garrett County Press; 2006.

409